prIME Downloadable Slides in Lung Cancer From the 2017 Oncology Annual Meeting in Chicago
0.75 AMA PRA Category 1 Credit™
Jun 15, 2017
Jun 15, 2018
- Jamie E. Chaft, MD, Memorial Sloan Kettering Cancer Center, New York, New York, United States
Abstract #8508: Neoadjuvant nivolumab in early-stage, resectable non-small cell lung cancers
- Julie Brahmer, MD, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, Maryland, United States
Abstract #9000: Progression after the next line of therapy (PFS2) and updated OS among patients (pts) with advanced NSCLC and PD-L1 tumor proportion score (TPS) ≥50% enrolled in KEYNOTE-024
- Fernando Costa Santini, MD, Memorial Sloan Kettering Cancer Center, New York, New York, United States
Abstract #9012: Safety of retreatment with immunotherapy after immune-related toxicity in patients with lung cancers treated with anti-PD(L)-1 therapy
- Ahmad Tarhini, MD , University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania
Abstract #9014: Efficacy and safety of epacadostat plus pembrolizumab treatment of NSCLC: Preliminary phase I/II results of ECHO-202/KEYNOTE-037
This activity is specifically designed to meet the needs of medical, surgical, and radiation oncologists, hematologists, and other healthcare professionals involved in the treatment of patients with cancer.
After successful completion of this educational activity, participants should be able to:
- Evaluate best practices regarding the treatment of patients with cancer, including integration of novel therapeutic approaches and individualization of care
This educational activity is supported by a grant from Merck and Co., Inc.
prIME Oncology is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
prIME Oncology designates this enduring activity for a maximum of 0.75 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This activity is provided by prIME Oncology.
Method of Participation
Links to the posttest are available on the video player pages.
In order to receive credit, participants must successfully complete the online posttest with 100%.
Disclosure of Relevant Financial Relationships
prIME Oncology assesses relevant financial relationships with its instructors, planners, managers, and other individuals who are in a position to control the content of CME activities. Any potential conflicts of interest that are identified are thoroughly vetted by prIME Oncology for fairness, balance, and scientific objectivity of data, as well as patient care recommendations. prIME Oncology is committed to providing its learners with high-quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial entity.
Dr Brahmer has disclosed that she has received consulting fees from Bristol-Myers Squibb (uncompensated), Celgene, Lilly, and Merck. She has performed contracted research for Bristol-Myers Squibb, MedImmune/Astrazeneca, and Merck. She has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in her presentation.
Dr Chaft has disclosed that she has received consulting fees from AstraZeneca, Bristol-Myers Squibb, Genentech, and Merck. She has agreed to disclose any unlabeled/unapproved uses of drugs referenced in her presentation.
Dr Santini has no relevant financial relationships to disclose. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.
Dr Tarhini has disclosed that he has performed contracted research for Incyte and Merck. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.
The employees of prIME Oncology have disclosed:
- Elizabeth Cameron, PhD (clinical content planner/reviewer) – no relevant financial relationships
- Christi Gray (editorial content reviewer) – no relevant financial relationships
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Disclosure Regarding Unlabeled Use
This activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration or European Medicines Agency. Please refer to the official prescribing information for each product discussed for discussions of approved indications, contraindications, and warnings.